AU662162B2 - Colorimetric determination of magnesium ions in fluids - Google Patents
Colorimetric determination of magnesium ions in fluids Download PDFInfo
- Publication number
- AU662162B2 AU662162B2 AU23259/92A AU2325992A AU662162B2 AU 662162 B2 AU662162 B2 AU 662162B2 AU 23259/92 A AU23259/92 A AU 23259/92A AU 2325992 A AU2325992 A AU 2325992A AU 662162 B2 AU662162 B2 AU 662162B2
- Authority
- AU
- Australia
- Prior art keywords
- reagent
- magnesium
- detergent
- complexing agent
- ions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 title claims description 31
- 229910001425 magnesium ion Inorganic materials 0.000 title claims description 31
- 239000012530 fluid Substances 0.000 title claims description 29
- 239000003153 chemical reaction reagent Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 39
- 239000008139 complexing agent Substances 0.000 claims description 15
- 239000003599 detergent Substances 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 12
- NJZWLEZSGOTSHR-UHFFFAOYSA-N 3-[(2-arsonophenyl)diazenyl]-4,5-dihydroxynaphthalene-2,7-disulfonic acid Chemical compound OC1=C2C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=C1N=NC1=CC=CC=C1[As](O)(O)=O NJZWLEZSGOTSHR-UHFFFAOYSA-N 0.000 claims description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 8
- 229910001424 calcium ion Inorganic materials 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 229910001427 strontium ion Inorganic materials 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 6
- 230000002452 interceptive effect Effects 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 claims description 5
- 230000031700 light absorption Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- -1 calcium ions Chemical class 0.000 claims description 4
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 229920004896 Triton X-405 Polymers 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 3
- 239000011777 magnesium Substances 0.000 description 29
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 27
- 229910052749 magnesium Inorganic materials 0.000 description 27
- 239000000975 dye Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 20
- VBRNLOQCBCPPHL-UHFFFAOYSA-N calmagite Chemical compound CC1=CC=C(O)C(N=NC=2C3=CC=CC=C3C(=CC=2O)S(O)(=O)=O)=C1 VBRNLOQCBCPPHL-UHFFFAOYSA-N 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- 238000004737 colorimetric analysis Methods 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- LVKZSFMYNWRPJX-UHFFFAOYSA-N phenylarsonic acid Chemical compound O[As](O)(=O)C1=CC=CC=C1 LVKZSFMYNWRPJX-UHFFFAOYSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020669 Hypermagnesaemia Diseases 0.000 description 2
- 206010021027 Hypomagnesaemia Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- JSSROCUNTZVPCI-UHFFFAOYSA-N chembl2002567 Chemical compound CC1=CC(C)=CC=C1NC(=O)C1=CC2=CC=CC=C2C(N=NC=2C(=CC=CC=2)O)=C1O JSSROCUNTZVPCI-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 229940117927 ethylene oxide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N 4-nonylphenol Chemical compound CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- SXYCCJAPZKHOLS-UHFFFAOYSA-N chembl2008674 Chemical compound [O-][N+](=O)C1=CC=C2C(N=NC3=C4C=CC=CC4=CC=C3O)=C(O)C=C(S(O)(=O)=O)C2=C1 SXYCCJAPZKHOLS-UHFFFAOYSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- LKSHJHJGLORTGD-UHFFFAOYSA-M sodium 3-[[3-[(2,4-dimethylphenyl)carbamoyl]-2-hydroxynaphthalen-1-yl]diazenyl]-4-hydroxybenzenesulfonate Chemical compound [Na+].CC1=C(C=CC(=C1)C)NC(=O)C=1C(=C(C2=CC=CC=C2C1)N=NC=1C=C(C=CC1O)S(=O)(=O)[O-])O LKSHJHJGLORTGD-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- DIZZDZCUMBBRSG-UHFFFAOYSA-J tetrasodium;2-[[5-[3-[3-[[bis(carboxylatomethyl)amino]methyl]-4-hydroxy-2-methyl-5-propan-2-ylphenyl]-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-2-hydroxy-6-methyl-3-propan-2-ylphenyl]methyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CC1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=C(CN(CC([O-])=O)CC([O-])=O)C(O)=C(C(C)C)C=2)C)=C1C DIZZDZCUMBBRSG-UHFFFAOYSA-J 0.000 description 1
- BWBONKHPVHMQHE-UHFFFAOYSA-N tiocarlide Chemical compound C1=CC(OCCC(C)C)=CC=C1NC(=S)NC1=CC=C(OCCC(C)C)C=C1 BWBONKHPVHMQHE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
i; ii ti- ;i; ni~ OPI DATC 02/03/93 AOJP DATE 13/05/93 APPLN. ID 23259/92 1 PCT NUMBER PCT/AU92/00359 I AU9223259 INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 5 (11) International Publication Number: WO 93/03100 C9B 67/36, 45/01, G01N 21/03 Al (43) International Publication Date: 18 February 1993 (18.02.93) G01N 21/78, 33/48, 33/49 (21) International Application Number: PCT/AU92/00359 (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, (22) International Filing Date: 16 July 1992 (16.07.92) MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, Priority data: CI, CM, GA, GN, ML, MR, SN, TD, TG).
PK 7466 26 July 1991 (26.07.91) A" Published (71) Applicant (for all designated States except US): SEBA DI- With international search report.
AGNOSTICS PTY. LTD. [AU/AU]; 26 Madden Grove, Burnley, VIC 3121 (AU).
(72) Inventors; and Inventors/Applicants (for US only) BALAZS, Nicholas, Dennis, Henry [AU/AU]; 26 Madden Grove, Burnley, VIC 3121 SECOMBE, John, William [AU/AU]; 32 Wave Street, Elwood, VIC 3184 (AU).
(74) Agents: SLATTERY, John, Michael et al.; Davies Collison Cave, 1 Lt. Collins Street, Melbourne, VIC 3000 (AU).
(54)Title: COLORIMETRIC DETERMINATION OF MAGNESIUM IONS IN FLUIDS (57) Abstract A method and reagent for the colorimetric determination of magnesium in a fluid. The method comprises contacting a sample of the fluid with the reagent comprising the metallochromic dye substance, 2-(4,5-dihydroxy-2,7-disulpho-3-naphthylazo)benzene-arsonic acid [Arsenoazo together with a selective complexing agent for removing interfering cations, particularly calcium ions and determining the formation of a magnesium-dye complex. A device for use in the method, comprising the reagent deposited on or impregnated inty solid support or carrier is also disclosed.
-i 3S:~ WO 93/03100 FCTAU92/00359 -1- COLORIMETRIC DETERMINATION OF MAGNESIUM IONS IN FLUIDS This invention relates to the colorimetric determination of magnesium ions in fluids, particularly in biological fluids such as blood serum, blood plasma, urine and the like. In particular, the invention relates to a colorimetric method for the quantitative analysis of the concentration of magnesium ions in such fluids.
Magnesium is quantitatively the second most abundant intracellular cation and is the fourth most abundant cation overall in the body. The mechanism of magnesium control within the body has not been fully elucidated however the narrow limits of normal plasma magnesium (0.7 to 1.0 mmol/1) impiy close homeostatic control. Magnesium measurements in biological fluids are relevant in both magnesium deficiency (hypomagnesaemia) and magnesium excess (hypermagnesaemia).
Hypomagnesaemia can result from: abnormal loss eg. diarrhoea, malabsorption, renal tubular acidosis, diuretic therapy, hyperparathyroidism etc; or (ii) reduced intake eg. severe prolonged malnutrition.
i i
I
r I'i
X
Hypermagnesaemia can result from: acute or chronic renal failure; (ii) haemodialysis against a fluid with a high magnesium content (hard water); or adrenocortical hypofunction. (iii) Plasma (or serum) and urine magnesium estimations are a useful indicator of.
total body magnesium homeostasis.
7)
I
WO 93/03100 PC/AU90/00350 -2- Modern methods for the assay of magnesium ions include both atomic absorption spectrophotometry and colorimetric dye-complexing methods.
Atomic absorption spectrophotometry is perhaps the best method for the determination of magnesium ions in fluids, however this method requires expensive instrumentation. More recent methods for magnesium determination have been colorimetric dye-complexing methods which rely on the formation of a coloured complex of magnesium ions with a metallochromic dye.
In general, colorimetric methods usually involve the addition of an aqueous dye-containing reagent to the sample fluid resulting in the formation of a coloured magnesium-dye complex having a characteristic wavelength of maximum light absorption. By exposing the sample of the fluid containing the complexed dye reagent to a light source of the characteristic wavelength, and thereafter measuring the degree of light absorption, the content of magnesium ions in the sample fluid can be simply determined from a graph constructed from absorbance measurements made on standard solutions containing known concentrations of magnesium ions.
In Australia, the most popular colorimetric method for the determination of magnesium ions at present is a method involving the metallochromic dye, Calmagite which is used in about 50% of magnesium determinations. A further 20% of determinations use the dye Magon, -;:hilst about 12% of determinations are patrr ned using atomic absorotion sectrophotometry. The remainder of determinations are performed using other miscellaneous colorimetric dye-complexing procedures, including those using such dyes as Eriochrome Black P and Methylthymol Blue.
One of the major difficulties which is encountered with magnesium determination using the dye Magon (Xylidyl Blue) is that citrate interferes with the reaction of magnesium ions with the dye. The result is that sample fluids containing citrate such as citrated-plasma specimens or specimens from WO 93/03100 PCT/AU92/00359 -3patients who have recently received intravenous solutions containing citrate, including blood transfusions, are precluded from analysis due to inaccurate results.
In the most popular colorimetric method using the metallochromic dye, Calmagite, [1-(1-hydroxy-4-methyl-2-phenylazo)-2-naphthol-4-sulfonic acid], the working reagent containing Calmagite, bound to a mixture of the 9ethyleneoxide adduct of p-nonylphenyl(Bion NE-9) and polyvinylpyrrolidone (Bion PVP), is added to a sample such as a serum sample and the magnesium ions in the sample cause the formation of a pink magnesium-Calmagite complex which is measured at 532nm. The presence of polyvinylpyrrolidone and the 9-ethyleneoxide adduct of p-nonylphenyl prevents interaction of protein in biological samples with the magnesium-Calmagite complex to influence the absorption spectrum of the complex which results in diminished accuracy of the measured magnesium ion concentration (see U.S. patent No.
3,754,864 to Gindler). The working reagent used in the Calmagite method also contains EGTA [ethylenebis(oxyethylenenitrilo)tetraacetic acid] to prevent calcium interference by preferential chelation of calcium ions, as well as potassium cyanide to prevent interference of heavy metals by formation of alternative complexes.
It is an object of the present invention to provide an alternative method for the accurate quantitative determination of magnesium ions in complex biological and aqueous sample fluids by a spectrophotometric method using a metallochromic dye, despite the presence of other potentially interfering J substances in the sample fluid.
In accordance with the present invention, there is provided a method for the colorimetric determination of magnesium ions in a fluid which comprises the step of contacting a sample of said fluid with a reagent comprising the metallochromic dye substance Arsenazo I [2-(4,5-dihydroxy-2,7disulpho-3-naphthylazo)benzene-arsonic acid] together with a selective (i WO 93/03100 PCT/AU92/00359 -4complexing agent, and determining the formation of a magnesium-dye complex.
Preferably, the step of determining the formation of a magnesium-dye complex is carried out by measurement of light absorption at 550-580nm, preferably at or near 568nm. The absorbance measurements obtained with the sample fluid are then compared with corresponding measurements made on standard solutions as in the previously known colorimetric methods.
In another aspect, the present invention also provides a reagent for the colorimetric determination of magnesium ions in fluids which comprises, in.
combination, the metallochromic dye substance, Arsenazo I together with a selective complexing agent.
Preferably the reagent has a pH in the range of 7.5 to 9.5, more preferably in the range of 8.5 to 8.8.
To the k 3wledge of the present inventors, Arsenazo I dye has not previously been used for the determination of magnesium ions in fluids as other cations, notably calcium ions, give a positive interference resulting in erroneous over-estimation of true magnesium ion concentration in complex biological fluids such as serum, plasma and urine. As broadly described above, the reagent used in accordance with the present invention includes a selective complexing agent which removes such interfering entities and permits the use of Arsenazo I dye to accurately measure magnesium ions free of interference.
The selective complexing agent which is used in the method and reagent of the present invention is preferably a highly selective complexing agent, most preferably BAPTA[1,2-bis(2-aminophenoxy)ethane-N,N,N,N l -tetraacetic acid] which has been found to be particularly effective in removing potentially interfering substances. Other selective complexing agents which may be used in accordance with the present invention include EGTA (as used in the 1 'i ;a WO 93/03100 PCT/AU92/00359 Calmagite method disclosed above). Whilst EGTA is inferior to BAPTA in that it has some affinity for magnesium, this problem can be overcome where EGTA is used as the selective complexing agent by addition of strontium ions to the reagent mixture. Strontium ions have a higher affinity for EGTA than magnesium ions but less affinity than calcium ions. As a result, calcium ions present in the sample being analysed will displace strontium ion and bind to the EGTA whereas magnesium ions will not, so that the magnesium ions in the sample will then be accurately analysed by complex formation with the Arsenazo I dye. It should be noted in this regard that where EGTA is used as the selective complexing agent together with strontium ions, the displaced strontium ions do not themselves interfere with the magnesium-dye complex formation.
As described above, the reagent used in the method of the present invention has a pH in the range 7.5 to 9.5, more preferably 8.5 to 8.7. Most 1 preferably the reagent is buffered to a mild alkaline pH using a buffer which does not bind metal ions. A particularly suitable buffer is tris(hydroxymethyl)amino methane (or Tris).
Preferably also, the reagent contains a detergent such as to solubilise protein where present in the sample fluid, particularly biological fluids such as serum, plasma and urine. Particularly suitable detergents include amphoteric detergents such as Empigen BB-AU, however other detergents which have been tested and found suitable for use in the reagent of the invention include Triton X-100, Triton X-405 and Brij 35. To date, however Empigen BB-AU is the surfactant/detergent which has proved to be the most efficient protein solubiliser.
Finally, the reagent used in the method of this invention may include other components which play no part in the reaction, for example sodium azide may be added as a preservative against fungal or bacterial growth in the reagent.
re 1 WO 93/03100 PCT/AU92/00359 -6- The method and reagent of the present invention can provide significant advantages in the determination of magnesium ions when compared with the Calmagite method described in detail above. In particular, whereas the Calmagite working reagent is usually made up from a kit supplying two separate reagents, namely a dye reagent (containing Calmagite, Bion NE-9 and Bio PVP) and a base reagent (containing potassium cyanide, potassium hydroxide and EGTA), the reagent of the present invention can be supplied as a single reagent buffered to a mild alkaline pH, which has an excellent closed container stability (greater than 2 years) at ambient temperatures.
Refrigeration is not required. Furthermore, the reagent of the present invention does not require the addition of components such as pdlyvinylpyrrolidone and the 9-ethylene oxide adduct of p-nonylphenol to prevent interference by proteins from the sample fluid. The method and reagent of the present invention also provide very rapid (almost instant) colour formation with the chromogenic magnesium-dye complex product being stable for an extended period (in excess of 12 hours). The method is also accurate and excellent agreement is obtained when compared with the results obtained using atomic absorption spectrophotometry as a reference method. Finally, the method and reagent of the present invention provide for accurate i 20 measurement without interference from calcium ions even at grossly elevated calcium concentrations (greater than 6 mmol/1).
While the foregoing description of the method and reagent of this invention refers most particularly to "wet" systems utilising a reagent in liquid form, the reagent of this invention may also be used in "dry" analytical systems in which the reagent is deposited on or impregnated into a solid support or carrier, for example a plastics material film or a porous solid support. In such "dry" systems, the water content of the sample being analysed rehydrates the reagent and the color change resulting from formation of the magnesium dye complex proceeds on the solid support or carrier. Formation of the magnesium dye complex is then determined either by absorbance (in the case j i I i WO 93/03100 PCT/AU92/00359 -7of a transparent support or carrier) or reflectance (in the case of an opaque support or carrier).
Further details of the method and reagent of the present invention, and of the accuracy and stability of the method of the present invention for the colorimetric determination of magnesium ions in sample fluids, are disclosed in the following examples and in the accompanying drawings. It should be noted that these examples are included by way of illustration of the present invention, and not by way of limitation.
Example 1 Reagent of the present invention A preferred reagent is an aqueous composition comprising: 0.080 g/L Arsenazo I [2-(4,5-dihydroxy-2,7-disulpho-3-naphthylazo) benzene-arsonic acid] 0.125 g/L BAPTA [1,2-bis(2-aminophenoxy)ethene- tetraacetic acid] ml/L Empigen BB-AU 12 g/L Tris 1 g/L Sodium Azide.
The pH of this solution is adjusted to 8.7 8.8 with hydrochloric acid.
Experimental procedure for determination of magnesium ions.
Using suitably accurate and precise pipetting devices, 25 microlitres of magnesium ion calibration solution or sample to be analysed are added to tubes containing 1.50 ml. of the reagent of the present invention as described -n above. Each tube is mixed thoroughly and the absorbance of each tube read at 568 nm against a blank tube containing 1.50 ml of reagent and 25 microlitres of pure water.
I -i WO 93/03100 PCT/AU92/00359 -8- The magnesium ion concentration of the sample (unknown) is calculated as follows: Mg. conc. of [Mg. cone. of calibrator] Absorb. of unknown X unknown Absorb. of calibrator Example 2 Comparison with atomic absorption spectrophotometry
(AAS).
Twenty-one randomly selected patient specimens (serum and plasma) were analysed in duplicate using the reagent and experimental procedure of Example 1 and a Roche Cobas Bio automated analyser, and by atomic adsorption spectroscopy (AAS) performed independently by a private consulting laboratory. The results are set out in Figure 1. Both set of results were obtained using a primary aqueous magnesium calibrator of 1.00 mmol/l concentration.
Example 3 Effect of added calcium.
Increasing amounts of a concentrated aqueous calcium solution mmol/1) were added to a human serum pool (magnesium 0.80 mmol/1, calcium 2.40 mmol/1) to give a final calcium concentration of 6.4 mmol, 1. The magnesium levels in this series were then assayed in accordance with Example 1, and demonstrated no interference from the added calcium. The results are shown in Figure 2.
Eanple 4 Reagent sltabily.
Most colorimetric magnesium determinat on methods use highly alkaline reaction mixtures. These have a major disadvantage in that they are relatively unstable, particularly in "open" vessels as used on several automated analysers. In these systems, and to a lesser extent in closed systems the 1 WO 93/03100 PCT/AU92/00359 -9alkaline reagent absorbs atmospheric carbon dioxide which leads to a pH change in the reagent, altering performance characteristics and requiring constant recalibration of the assay.
Figure 3 shows data from solutions of the reagent of Example 1 with and without magnesium, and Calmagite reagent with and without magnesium.
The solutions were left in open vessels and their respective absorbances monitored over a 24 hour period. As can be seen, the absorbances in the Calmagite solutions are not stable, whereas a slight increase in absorbance is shown with the present reagent, believed to be due to evaporation only.
Example 5 Absorbance versus time.
Human serum was mixed with the reagent of Example 1 and the absorbance monitored over 30 minutes. The results are shown in Figure 4.
The earliest possible reading on the spectrophotometer in use was 5 seconds, and the results show that there was no detectable absorbance change from seconds through to 30 mirutes. Most automated instruments have an ideal measuring "window" of time from about 1 minute through to 15 minutes depending on the instrmnent.
Example 6 Magnesium recovery.
Increasing amounts of a concentrated magnesium solution were added to a human serum with a low magnesium value (0.25 mmol/1). Theoretical magnesium concentration of the "spiked" solutions is plotted in Figure against the values recovered when the solutions were measured with the reagent of Example 1. Recovery was in the range of 98 to 101% up to 2 nmmol/1.
N'
'N
WO 93/03100 P I/AU92/00359 10 Example 7 Absorbance verszs concentration.
Aqueous primary magnesium calibration material was prepared by diluting a commercial AAS magnesium calibrator, from 0.25 to 2.00 mmol/l.
These calibrators were analysed with the reagent of Example 1 and absorbance versus concentration plotted in Figure 6. Linearity to 2.0 mmol/1 was demonstrated.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all.
such variations and modifications which fall within its spirit and scope. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.
i I I
K
a
Claims (17)
1. A method for the colorimetric determination of magnesium ions in a fluid, which comprises the step of contacting a sample of said fluid with a reagent comprising the metallochromic dye substance, 2-(4,5-dihydroxy-2,7- disulpho-3-naphthylazo)benzene-arsonic acid [Arsenoazo together with a selective competxing agent, and determining the formation of a magnesium-dye complex.
2. A method according to claim 1, wherein said determination of the formation of a magnesium-ye complex is carried out by measurement of light absorption of 550-580nm.
3. A method according to claim 2, wherein said determination is carried out by measurement of light absorption or near 568nm.
4. A method according to any of claims 1 to 3, wherein said selective complexing agent removes interfering cations, particularly calcium ions, from said fluid sample. A method according to claim 4, wherein said selective complexing agent is 1,2-bis(2-aminophenoxy)ethane-N,N ',N',-tetracetic acid [BAPTA]. 1 6. A method according to claim 4, wherein said selective complexing agent is ethylenebis(oxyethylenenitrilo)tetraacc'ic acid [EGTA]. 7, A method according to claim 6, wherein said reagent further comprises strontium ions.
8. A method according to any of claims 1 to 7, wherein said reagent is buffered to a pH in the range 7.5 to 9.5, preferably 8.5 to 8.7. o WO 93/03100 PCT/AU92/00359 -12-
9. A method according to claim 8, wherein said reagent comprises the buffer tris(hydroxymethyl)amino methane [TRIS]. A method according to any of claims 1 to 9, wherein said reagent further comprises a detergent to solubilise any protein present in said fluid sample.
11. A method according to claim 10 wherein said detergent is an amphoteric detergent, preferably Empigen BB-AU.
12. A method according to claim 10 wherein said detergent is selected from Triton X-100, Triton X-405 and Brij 13, A reagent for the colorimetric determination of magnesium ions in fluids which comprises in combination, the metallochromic dye substance, 2- (4,5-dihydroxy-2,7-disulpho-3-naphthylazo)benzene-arsonic acid [Arsenoazo I], together with a selective complexing agent.
14. A reagent according to claim 13, wherein said selective complexing agent removes interfering cations particularly calcium ions. A reagent according to claim 14, wherr n said selective complexing agent is 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetracetic acid [BAPTA].
16. A reagent according to claim 14, wherein said selective complexing agent is ethylenebis(oxyethylenenitrilo)tetraacetic acid [EGTA].
17. A reagent according to claim 16, further comprising strontium ions.
18. A reagent according to any of claims 13 to 17, which is buffered to a pH in the range 7.5 to 9.5, preferably 8.5 to 8.7. I; /I i i WO 93/03100 1 PCT/AU92/0359 -13- 4
19. A reagent according to claim 18 further comprising the buffer tris(hydroxymethyl)amino methane ITRIS]. A reagent according to any of claims 13 to 19, further comprising a detergent.
21. A reagent according to claim 20, wherein said detergent is an amphoteric detergent, preferably Empigen BB-AU.
22. A reagent according to claim 20, wherein said detergent is selected from Triton X-100, Triton X-405 and Brij
23. A device for use in the colorimetric determination of magnesium ions in fluids, which comprises a solid support or carrier, and a reagent according to any of claims 13 to 22 deposited on or impregnated into said support or carrier.
24. A device according to claim 23, wherein said solid support or carrier comprises plastics material film or a porous solid support. I Y i i i it i ::1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU23259/92A AU662162B2 (en) | 1991-07-26 | 1992-07-16 | Colorimetric determination of magnesium ions in fluids |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPK746691 | 1991-07-26 | ||
AUPK7466 | 1991-07-26 | ||
PCT/AU1992/000359 WO1993003100A1 (en) | 1991-07-26 | 1992-07-16 | Colorimetric determination of magnesium ions in fluids |
AU23259/92A AU662162B2 (en) | 1991-07-26 | 1992-07-16 | Colorimetric determination of magnesium ions in fluids |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2325992A AU2325992A (en) | 1993-03-02 |
AU662162B2 true AU662162B2 (en) | 1995-08-24 |
Family
ID=25618861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU23259/92A Ceased AU662162B2 (en) | 1991-07-26 | 1992-07-16 | Colorimetric determination of magnesium ions in fluids |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU662162B2 (en) |
-
1992
- 1992-07-16 AU AU23259/92A patent/AU662162B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2325992A (en) | 1993-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2183558C (en) | Cyanide-free reagent and method for the determination of hemoglobin | |
Ceriotti et al. | Improved direct specific determination of serum iron and total iron-binding capacity. | |
Peterson et al. | Spectrophotometric determination of serum copper with biscyclohexanoneoxalyldihydrazone | |
US3754865A (en) | Colorimetric determination of calcium in biologic fluids | |
US4308027A (en) | Method and composition for direct determination of iron in blood serum | |
GarĨic | A highly sensitive, simple determination of serum iron using chromazurol B | |
AU617300B2 (en) | Reagent and procedure for determining cations | |
JP3524602B2 (en) | Method for analyzing protein in urine and composition for measuring the same | |
JPH04287695A (en) | Composition for analyzing ethanol | |
US4372747A (en) | Glycohemoglobin determination | |
Nakamura et al. | Highly sensitive spectrophotometric and spectrofluorometric determinations of albumin with 5, 10, 15, 20-tetrakis (4-sulfophenyl) porphine | |
WO1983002670A1 (en) | Assay method and reagent for the determination of chloride | |
AU662162B2 (en) | Colorimetric determination of magnesium ions in fluids | |
US4529708A (en) | Assay for the determination of creatinine | |
EP0597900B1 (en) | Colorimetric determination of magnesium ions in fluids | |
US4278440A (en) | Reagent and method for direct determination of chloride in serum | |
US3822116A (en) | Reagent and method for calcium determination | |
Wong et al. | Colorimetric determination of potassium in whole blood, serum, and plasma. | |
US4030885A (en) | Bilirubin determination | |
RU2253864C1 (en) | Indicator composition for joint determination of copper(ii) and manganese(ii) in aqueous solutions | |
US3836332A (en) | Determination of vanilmandelic acid in urine | |
JPS6314303B2 (en) | ||
RU2085915C1 (en) | Method of quantitative determination of potassium cyanide | |
JPH02122267A (en) | Hemoglobin quantitative reagent kit and hemoglobin quantitative method using the same | |
JPH04361160A (en) | Measurement of protein |